235 related articles for article (PubMed ID: 25426996)
1. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
[TBL] [Abstract][Full Text] [Related]
2. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
3. Decreased serum bone specific alkaline phosphatase and increased urinary N-terminal telopeptide of type I collagen as prognostic markers for bone mineral density loss in HIV patients on cART.
Koga I; Seo K; Yoshino Y; Kitazawa T; Kurahashi I; Ota Y
J Infect Chemother; 2016 Aug; 22(8):543-7. PubMed ID: 27346381
[TBL] [Abstract][Full Text] [Related]
4. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
5. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults.
Wattanachanya L; Jantrapakde J; Avihingsanon A; Ramautarsing R; Kerr S; Trachunthong D; Pussadee K; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Phanuphak N; Sunthornyothin S; Phanuphak P;
AIDS Care; 2020 Aug; 32(8):984-993. PubMed ID: 31137948
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of bone density in human immunodeficiency virus-infected women.
Dolan SE; Kanter JR; Grinspoon S
J Clin Endocrinol Metab; 2006 Aug; 91(8):2938-45. PubMed ID: 16735489
[TBL] [Abstract][Full Text] [Related]
8. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
[TBL] [Abstract][Full Text] [Related]
11. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
12. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
[TBL] [Abstract][Full Text] [Related]
13. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
Brzóska MM; Moniuszko-Jakoniuk J
Bone; 2004 Nov; 35(5):1180-91. PubMed ID: 15542044
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
17. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
[TBL] [Abstract][Full Text] [Related]
18. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
[TBL] [Abstract][Full Text] [Related]
19. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
20. [A comparison of the measurements with biochemical markers of bone turnover and bone mineral density in the assessment of the efficiency of osteoporosis treatment].
Ataoğlu MB; Atik OŞ; Gül O; Sarıkaya B; Görmeli G; Öztürk BY; Özgürol B
Eklem Hastalik Cerrahisi; 2013; 24(2):82-6. PubMed ID: 23692194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
